Resources

Whole-Body MRI: A Call for Clarity, Not Cancellation

Back to Resources
Download PDF

The team behind Whole Body MRI Pty Ltd and MBR Health were recently asked to respond to an AusDoc article published featuring RANZCR’s lead voice, Professor John Slavotinek, who shared his concerns regarding full-body MRI use among asymptomatic individuals for screening. Although the article is behind a free-account wall, his concerns mirrored the latest RANZCR position statement which does not recommend whole-body MRI as a result of no evidence of survival benefit, risk of incidental findings, anxiety and resource burden.

Unfortunately, many of our crucial response points did not make the final published AusDoc news article on 04 Dec 2025. To clarify our position, we have provided our full response to AusDoc below. 

 

AusDoc: Does the RANZCR president have a point about whole-body MRI? Is there a downside? 

RANZCR’s position highlights the lack of evidence for mortality benefit in low-risk individuals and the possibility that incidental or indeterminate findings may lead to unnecessary investigation. These concerns are valid.

However, the statement does not address the lack of image acquisition and reporting standards (e.g. ONCO-RADS) nor expectations around radiologist experience for whole-body MRI.  While not incorrect, the College emphasises on the downstream consequences without addressing the upstream problem: inconsistency.  

Currently there is vast heterogeneity among whole-body MRI protocols, both in the literature and in clinical practice. Systematic reviews highlight that the quality of imaging parameters such as resolution, number of tissue weights, inclusion of DWI influences the likelihood of false-positives and indeterminate findings (Kwee & Kwee 2019).

Yet the College’s position statement does not comment on the harms created by inconsistent practice, nor does it propose standardisation as the potential solution. 

The suggestion that whole-body MRI is largely commercially driven also overlooks broader shifts in patient behaviour and epidemiology. Early-onset cancers (< 50 years) are rising across several cancer types, particularly bowel, oesophageal, pancreatic, breast and prostate cancer with many affected individuals falling outside established screening pathways. For instance, the risk of developing pancreatic cancer has been on the rise since the start of the century, with an observed 200% increase among individuals aged 30-39 (Australian Institute of Health). By 2030, pancreatic cancer is on track to be the second most common cause of cancer-related mortality (Rahib L Et al 2014). 

Additionally, modern patients are more informed, more health-literate and more engaged with preventative health than previous generations (De Silva et al 2023). They routinely research symptoms, understand risk frameworks and seek clarity rather than waiting for illness to declare itself – seeking “proof of wellness”. In this context, demand for whole-body MRI reflects a gap in current preventative health structures and shifting patient expectations rather than a response to marketing. 

 

AusDoc: Do whole-body MRIs improve outcomes for asymptomatic people? 

The answer depends on how outcome is defined. If improvement refers exclusively to mortality reduction demonstrated through decades of prospective research, then whole-body MRI has not yet been studied long enough to deliver that evidence.  

Interestingly, particularly in an era of AI derived biomarkers, it is also very possible that contemporary imaging will never produce traditional survival-curve endpoints because abnormalities are increasingly detected at stages before a natural disease course can be ethically observed. 

Modern clinical outcomes extend beyond mortality alone. For many, the priority is not only living longer but maintaining quality of life across those years. Avoiding late-stage diagnosis, earlier intervention and improving quality-adjusted life years are meaningful benefits, particularly for younger adults now affected by rising early-onset cancers who have no existing screening pathways. While we have anecdotal evidence, these quality-of-life outcomes also require further clinical research.  

However, it should be acknowledged that whole-body MRI is not for everyone. For individuals of advanced age (e.g. > 65) this scan is less likely to produce improved outcomes due the increased likelihood of detecting a condition that would have never gone on to harm the individual if left undetected. This phenomenon is known as “overdiagnosis” and is not unique to whole-body MRI, rather a well-recognised and unavoidable feature across all screening modalities (e.g. mammography, PSA testing). 

 

AusDoc: What about psychosocial anxiety and incidental findings? 

The assumption that whole-body MRI causes significant or lasting anxiety is not supported by evidence.  

In groups with the greatest reason for distress, such as carriers of high-risk genetic predispositions, longitudinal studies consistently report high acceptability and no deterioration in cancer worry, mood or other measures of psychosocial burden after whole-body MRI screening (Bancroft EK, et al. 2021 Omran M, et al 2023).  

General-population data are more limited, but the evidence available does not support increase anxiety from whole-body MRI, including the disclosure of incidental findings. In fact, studies show that individuals who opted to undergo whole-body MRI had lower psychosocial burden than those who did not receive a whole-body scan. Importantly, the disclosure of incidental findings was not associated with long-term adverse psychosocial outcomes, and in some cases, disclosure appeared to reduce worry further (Korbmacher-Böttcher et al 2022).  

Clear patient education significantly reduces unnecessary concern, and structured reporting systems such as ONCO-RADS (Petralia et al 2021), which categorise findings with linked management recommendations, help patients and clinicians understand what does and does not require follow-up. 

 

AusDoc: Are there opportunistic players in this space? 

As with any emerging medical technology that lacks formal standards, opportunistic providers inevitably appear. The core challenge is ensuring that individuals and health professionals understand that not all full-body MRI scans are created equal. Marketing claims such as “500 conditions” can be confusing and potentially misleading, giving the impression of comprehensive “catch-all” capability.

This scan is primarily intended and optimised for cancer-detection, and should be made clear that this is not a diagnostic tool for symptoms such as pain. 

 

AusDoc: Do you agree with the RANZCR position statement? 

We agree that poor-quality whole-body MRI should not be encouraged and that unnecessary follow-up triggered by unclear findings is undesirable.  

Where we diverge is in the blanket recommendation against [well-performed, clinical-grade] whole-body MRI in for well-informed, average-risk individuals. These individuals, fully understand both the direct risks such as erroneous findings and anxiety they may cause, and the indirect risks such as over-diagnosis. 

 

AusDoc: Any final thoughts? 

Medical innovation has always moved through phases of discomfort and debate (e.g. Semmelweis Reflex).   Whole-body MRI sits within that early transitional phase. It should neither be universally promoted nor categorically dismissed. Instead, focus should be on standardisation, transparently communicated and incorporated into shared, and well-informed decision-making for individuals whose risk patterns are not recognised by existing preventative frameworks. 

 

Related Articles

 
Author: A Forbes, PhD. Reviewed by Dr Zane Sherif, Co-founder and Radiologist

 

Download PDF

Journey into the known with a Whole Body MRI™ scan